Precision BioSciences

DTIL

Durham, United States· Est. 2006

precisionbiosciences.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

DTIL · Stock Price

USD 7.48+2.35 (+45.81%)

Market Cap: $197.7M

Historical price data

Market Cap: $197.7MPipeline: 5 drugsFounded: 2006Employees: 100-250HQ: Durham, United States

Overview

Precision BioSciences is a clinical-stage biotech leveraging its proprietary ARCUS genome editing platform to develop potentially curative in vivo therapies for genetic diseases. The company has advanced two wholly-owned programs into Phase 1/2 trials: PBGENE-HBV for chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy, both supported by key regulatory designations. Its strategy combines advancing these core assets with strategic partnerships to validate and fund the ARCUS platform, positioning it in the competitive but high-potential gene editing landscape.

Rare Genetic DiseasesInfectious Disease

Technology Platform

ARCUS is a proprietary genome editing platform using engineered homing endonucleases for precise DNA insertion, removal, or repair in vivo, with key advantages in size, specificity, and function in non-dividing cells.

Pipeline

5 drugs in pipeline

Drug	Indication	Stage
PBGENE-DMD (IV)	Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD	Phase 1/2
Fludarabine + Cyclophosphamide	Non-Hodgkin's Lymphoma, Relapsed	Phase 1/2
PBGENE-HBV	HEPATITIS B CHRONIC	Phase 1
Fludarabine + Cyclophosphamide + Nirogacestat	Relapsed/Refractory Multiple Myeloma	Phase 1
PBGENE-HBV	Chronic HBV Infection	Pre-clinical

Funding History

Total raised:$300M

IPO$145MUndisclosedMar 28, 2019

Series C$110MPontifaxJun 15, 2016

Series B$30MIntersouth PartnersJun 15, 2012

Series A$15MIntersouth PartnersJun 15, 2008

Opportunities

PBGENE-HBV addresses a global population of ~300 million with chronic HBV, where a functional cure represents a multi-billion dollar market.

PBGENE-DMD targets a severe, high-need pediatric neuromuscular disorder with limited treatment options, offering a one-time, potentially disease-modifying therapy for a broad patient subset.

Risk Factors

High clinical development risk inherent to novel in vivo gene editing; near-term liquidity risk with cash runway into H2 2026 necessitating dilutive financing or partnerships; intense competition in both HBV and DMD from alternative modalities and gene editing platforms.

Competitive Landscape

Faces competition in HBV from gene editing rivals (Intellia, Beam) and antiviral players, and in DMD from gene therapy (Sarepta) and other modalities. Precision's edge is the ARCUS platform's specific profile (small size, high specificity, activity in non-dividing cells) and first-mover clinical positioning in HBV.